Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
Identifieur interne : 000873 ( Ncbi/Merge ); précédent : 000872; suivant : 000874Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
Auteurs : Wagner Quintilio [Brésil] ; Flavia S. Kubrusly ; Dmitri Iourtov ; Cosue Miyaki ; Maria Aparecida Sakauchi ; Fernanda Lúcio ; Sandra De Cássia Dias ; Celia S. Takata ; Eliane N. Miyaji ; Hisako G. Higashi ; Luciana C C. Leite ; Isaias RawSource :
- Vaccine [ 1873-2518 ] ; 2009.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (isolement et purification), Adjuvants immunologiques (pharmacologie), Animaux, Anticorps antiviraux (sang), Bordetella pertussis (), Hydroxyde d'aluminium (pharmacologie), Immunoglobuline G (sang), Interféron gamma (métabolisme), Interleukine-4 (métabolisme), Lipide A (analogues et dérivés), Lipide A (isolement et purification), Lipide A (pharmacologie), Souris, Souris de lignée BALB C, Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (immunologie), Vaccins sous-unitaires (immunologie).
- MESH :
- analogues et dérivés : Lipide A.
- immunologie : Vaccins antigrippaux, Vaccins sous-unitaires.
- isolement et purification : Adjuvants immunologiques, Lipide A.
- métabolisme : Interféron gamma, Interleukine-4.
- pharmacologie : Adjuvants immunologiques, Hydroxyde d'aluminium, Lipide A.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Animaux, Bordetella pertussis, Souris, Souris de lignée BALB C, Tests d'inhibition de l'hémagglutination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (isolation & purification), Adjuvants, Immunologic (pharmacology), Aluminum Hydroxide (pharmacology), Animals, Antibodies, Viral (blood), Bordetella pertussis (chemistry), Hemagglutination Inhibition Tests, Immunoglobulin G (blood), Influenza Vaccines (immunology), Interferon-gamma (metabolism), Interleukin-4 (metabolism), Lipid A (analogs & derivatives), Lipid A (isolation & purification), Lipid A (pharmacology), Mice, Mice, Inbred BALB C, Vaccines, Subunit (immunology).
- MESH :
- chemical , analogs & derivatives : Lipid A.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Influenza Vaccines, Vaccines, Subunit.
- chemical , isolation & purification : Adjuvants, Immunologic, Lipid A.
- chemical , metabolism : Interferon-gamma, Interleukin-4.
- chemical , pharmacology : Adjuvants, Immunologic, Aluminum Hydroxide, Lipid A.
- chemistry : Bordetella pertussis.
- Animals, Hemagglutination Inhibition Tests, Mice, Mice, Inbred BALB C.
Abstract
The world production capacity of influenza vaccines is a concern in face of the potential influenza pandemic. The use of adjuvants could increase several fold the current installed production capacity. Bordetella pertussis monophosphyl lipid A (MPLA) was produced by acid hydrolysis of LPS, obtained as a by-product of its removal from cellular pertussis vaccine, generating a product with 4 side chains. We have investigated different formulations including MPLA alone or combined with Al(OH)(3) as adjuvants for an inactivated split virion influenza vaccine. Our results demonstrate that MPLA at concentrations as low as 0.01 microg per dose of vaccine is effective, even with a 4-fold reduction of the regular vaccine dose, as measured by the induction of protective hemagglutination inhibition (HAI) titers. Al(OH)(3) can be combined with 0.01-10 microg MPLA, inducing even higher immune responses. Al(OH)(3) caused a drift of the immune response induced by the vaccine towards a Th2 profile, as evaluated by an increase in the IgG1:IgG2a ratio, while MPLA showed a more balanced response. Moreover, the use of MPLA and Al(OH)(3) combination led to the induction of the highest IgG levels together with the secretion of both IFN-gamma and IL-4. Although cell-mediated immune responses have not been usually taken into account for influenza vaccine formulations, they may be relevant for the induction of cross-protection as well as immunological memory for both inter-pandemic and pandemic influenza vaccines. Our results indicate that a more favorable profile of both humoral and cell-mediated immune responses may be obtained using the MPLA/Al(OH)(3) formulation.
DOI: 10.1016/j.vaccine.2009.04.047
PubMed: 19393709
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001767
- to stream PubMed, to step Curation: 001767
- to stream PubMed, to step Checkpoint: 001659
Links to Exploration step
pubmed:19393709Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.</title><author><name sortKey="Quintilio, Wagner" sort="Quintilio, Wagner" uniqKey="Quintilio W" first="Wagner" last="Quintilio">Wagner Quintilio</name><affiliation wicri:level="2"><nlm:affiliation>BioIndustrial Division, Instituto Butantan, São Paulo, SP, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>BioIndustrial Division, Instituto Butantan, São Paulo, SP</wicri:regionArea><placeName><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Kubrusly, Flavia S" sort="Kubrusly, Flavia S" uniqKey="Kubrusly F" first="Flavia S" last="Kubrusly">Flavia S. Kubrusly</name></author><author><name sortKey="Iourtov, Dmitri" sort="Iourtov, Dmitri" uniqKey="Iourtov D" first="Dmitri" last="Iourtov">Dmitri Iourtov</name></author><author><name sortKey="Miyaki, Cosue" sort="Miyaki, Cosue" uniqKey="Miyaki C" first="Cosue" last="Miyaki">Cosue Miyaki</name></author><author><name sortKey="Sakauchi, Maria Aparecida" sort="Sakauchi, Maria Aparecida" uniqKey="Sakauchi M" first="Maria Aparecida" last="Sakauchi">Maria Aparecida Sakauchi</name></author><author><name sortKey="Lucio, Fernanda" sort="Lucio, Fernanda" uniqKey="Lucio F" first="Fernanda" last="Lúcio">Fernanda Lúcio</name></author><author><name sortKey="Dias, Sandra De Cassia" sort="Dias, Sandra De Cassia" uniqKey="Dias S" first="Sandra De Cássia" last="Dias">Sandra De Cássia Dias</name></author><author><name sortKey="Takata, Celia S" sort="Takata, Celia S" uniqKey="Takata C" first="Celia S" last="Takata">Celia S. Takata</name></author><author><name sortKey="Miyaji, Eliane N" sort="Miyaji, Eliane N" uniqKey="Miyaji E" first="Eliane N" last="Miyaji">Eliane N. Miyaji</name></author><author><name sortKey="Higashi, Hisako G" sort="Higashi, Hisako G" uniqKey="Higashi H" first="Hisako G" last="Higashi">Hisako G. Higashi</name></author><author><name sortKey="Leite, Luciana C C" sort="Leite, Luciana C C" uniqKey="Leite L" first="Luciana C C" last="Leite">Luciana C C. Leite</name></author><author><name sortKey="Raw, Isaias" sort="Raw, Isaias" uniqKey="Raw I" first="Isaias" last="Raw">Isaias Raw</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19393709</idno><idno type="pmid">19393709</idno><idno type="doi">10.1016/j.vaccine.2009.04.047</idno><idno type="wicri:Area/PubMed/Corpus">001767</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001767</idno><idno type="wicri:Area/PubMed/Curation">001767</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001767</idno><idno type="wicri:Area/PubMed/Checkpoint">001659</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001659</idno><idno type="wicri:Area/Ncbi/Merge">000873</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.</title><author><name sortKey="Quintilio, Wagner" sort="Quintilio, Wagner" uniqKey="Quintilio W" first="Wagner" last="Quintilio">Wagner Quintilio</name><affiliation wicri:level="2"><nlm:affiliation>BioIndustrial Division, Instituto Butantan, São Paulo, SP, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>BioIndustrial Division, Instituto Butantan, São Paulo, SP</wicri:regionArea><placeName><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Kubrusly, Flavia S" sort="Kubrusly, Flavia S" uniqKey="Kubrusly F" first="Flavia S" last="Kubrusly">Flavia S. Kubrusly</name></author><author><name sortKey="Iourtov, Dmitri" sort="Iourtov, Dmitri" uniqKey="Iourtov D" first="Dmitri" last="Iourtov">Dmitri Iourtov</name></author><author><name sortKey="Miyaki, Cosue" sort="Miyaki, Cosue" uniqKey="Miyaki C" first="Cosue" last="Miyaki">Cosue Miyaki</name></author><author><name sortKey="Sakauchi, Maria Aparecida" sort="Sakauchi, Maria Aparecida" uniqKey="Sakauchi M" first="Maria Aparecida" last="Sakauchi">Maria Aparecida Sakauchi</name></author><author><name sortKey="Lucio, Fernanda" sort="Lucio, Fernanda" uniqKey="Lucio F" first="Fernanda" last="Lúcio">Fernanda Lúcio</name></author><author><name sortKey="Dias, Sandra De Cassia" sort="Dias, Sandra De Cassia" uniqKey="Dias S" first="Sandra De Cássia" last="Dias">Sandra De Cássia Dias</name></author><author><name sortKey="Takata, Celia S" sort="Takata, Celia S" uniqKey="Takata C" first="Celia S" last="Takata">Celia S. Takata</name></author><author><name sortKey="Miyaji, Eliane N" sort="Miyaji, Eliane N" uniqKey="Miyaji E" first="Eliane N" last="Miyaji">Eliane N. Miyaji</name></author><author><name sortKey="Higashi, Hisako G" sort="Higashi, Hisako G" uniqKey="Higashi H" first="Hisako G" last="Higashi">Hisako G. Higashi</name></author><author><name sortKey="Leite, Luciana C C" sort="Leite, Luciana C C" uniqKey="Leite L" first="Luciana C C" last="Leite">Luciana C C. Leite</name></author><author><name sortKey="Raw, Isaias" sort="Raw, Isaias" uniqKey="Raw I" first="Isaias" last="Raw">Isaias Raw</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (isolation & purification)</term><term>Adjuvants, Immunologic (pharmacology)</term><term>Aluminum Hydroxide (pharmacology)</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Bordetella pertussis (chemistry)</term><term>Hemagglutination Inhibition Tests</term><term>Immunoglobulin G (blood)</term><term>Influenza Vaccines (immunology)</term><term>Interferon-gamma (metabolism)</term><term>Interleukin-4 (metabolism)</term><term>Lipid A (analogs & derivatives)</term><term>Lipid A (isolation & purification)</term><term>Lipid A (pharmacology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Vaccines, Subunit (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (isolement et purification)</term><term>Adjuvants immunologiques (pharmacologie)</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Bordetella pertussis ()</term><term>Hydroxyde d'aluminium (pharmacologie)</term><term>Immunoglobuline G (sang)</term><term>Interféron gamma (métabolisme)</term><term>Interleukine-4 (métabolisme)</term><term>Lipide A (analogues et dérivés)</term><term>Lipide A (isolement et purification)</term><term>Lipide A (pharmacologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins sous-unitaires (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Lipid A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Subunit</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Lipid A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Hydroxide</term><term>Lipid A</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Lipide A</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Bordetella pertussis</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins sous-unitaires</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Lipide A</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Interféron gamma</term><term>Interleukine-4</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Hydroxyde d'aluminium</term><term>Lipide A</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Hemagglutination Inhibition Tests</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bordetella pertussis</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Tests d'inhibition de l'hémagglutination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The world production capacity of influenza vaccines is a concern in face of the potential influenza pandemic. The use of adjuvants could increase several fold the current installed production capacity. Bordetella pertussis monophosphyl lipid A (MPLA) was produced by acid hydrolysis of LPS, obtained as a by-product of its removal from cellular pertussis vaccine, generating a product with 4 side chains. We have investigated different formulations including MPLA alone or combined with Al(OH)(3) as adjuvants for an inactivated split virion influenza vaccine. Our results demonstrate that MPLA at concentrations as low as 0.01 microg per dose of vaccine is effective, even with a 4-fold reduction of the regular vaccine dose, as measured by the induction of protective hemagglutination inhibition (HAI) titers. Al(OH)(3) can be combined with 0.01-10 microg MPLA, inducing even higher immune responses. Al(OH)(3) caused a drift of the immune response induced by the vaccine towards a Th2 profile, as evaluated by an increase in the IgG1:IgG2a ratio, while MPLA showed a more balanced response. Moreover, the use of MPLA and Al(OH)(3) combination led to the induction of the highest IgG levels together with the secretion of both IFN-gamma and IL-4. Although cell-mediated immune responses have not been usually taken into account for influenza vaccine formulations, they may be relevant for the induction of cross-protection as well as immunological memory for both inter-pandemic and pandemic influenza vaccines. Our results indicate that a more favorable profile of both humoral and cell-mediated immune responses may be obtained using the MPLA/Al(OH)(3) formulation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19393709</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>31</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.</ArticleTitle><Pagination><MedlinePgn>4219-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2009.04.047</ELocationID><Abstract><AbstractText>The world production capacity of influenza vaccines is a concern in face of the potential influenza pandemic. The use of adjuvants could increase several fold the current installed production capacity. Bordetella pertussis monophosphyl lipid A (MPLA) was produced by acid hydrolysis of LPS, obtained as a by-product of its removal from cellular pertussis vaccine, generating a product with 4 side chains. We have investigated different formulations including MPLA alone or combined with Al(OH)(3) as adjuvants for an inactivated split virion influenza vaccine. Our results demonstrate that MPLA at concentrations as low as 0.01 microg per dose of vaccine is effective, even with a 4-fold reduction of the regular vaccine dose, as measured by the induction of protective hemagglutination inhibition (HAI) titers. Al(OH)(3) can be combined with 0.01-10 microg MPLA, inducing even higher immune responses. Al(OH)(3) caused a drift of the immune response induced by the vaccine towards a Th2 profile, as evaluated by an increase in the IgG1:IgG2a ratio, while MPLA showed a more balanced response. Moreover, the use of MPLA and Al(OH)(3) combination led to the induction of the highest IgG levels together with the secretion of both IFN-gamma and IL-4. Although cell-mediated immune responses have not been usually taken into account for influenza vaccine formulations, they may be relevant for the induction of cross-protection as well as immunological memory for both inter-pandemic and pandemic influenza vaccines. Our results indicate that a more favorable profile of both humoral and cell-mediated immune responses may be obtained using the MPLA/Al(OH)(3) formulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quintilio</LastName><ForeName>Wagner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>BioIndustrial Division, Instituto Butantan, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubrusly</LastName><ForeName>Flavia S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Iourtov</LastName><ForeName>Dmitri</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Miyaki</LastName><ForeName>Cosue</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sakauchi</LastName><ForeName>Maria Aparecida</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Lúcio</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Sandra de Cássia</ForeName><Initials>Sde C</Initials></Author><Author ValidYN="Y"><LastName>Takata</LastName><ForeName>Celia S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Miyaji</LastName><ForeName>Eliane N</ForeName><Initials>EN</Initials></Author><Author ValidYN="Y"><LastName>Higashi</LastName><ForeName>Hisako G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Luciana C C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Raw</LastName><ForeName>Isaias</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008050">Lipid A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>5QB0T2IUN0</RegistryNumber><NameOfSubstance UI="D000536">Aluminum Hydroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>MWC0ET1L2P</RegistryNumber><NameOfSubstance UI="C048436">monophosphoryl lipid A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000536" MajorTopicYN="N">Aluminum Hydroxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001886" MajorTopicYN="N">Bordetella pertussis</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008050" MajorTopicYN="N">Lipid A</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19393709</ArticleId><ArticleId IdType="pii">S0264-410X(09)00600-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2009.04.047</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Brésil</li></country><region><li>État de São Paulo</li></region></list><tree><noCountry><name sortKey="Dias, Sandra De Cassia" sort="Dias, Sandra De Cassia" uniqKey="Dias S" first="Sandra De Cássia" last="Dias">Sandra De Cássia Dias</name><name sortKey="Higashi, Hisako G" sort="Higashi, Hisako G" uniqKey="Higashi H" first="Hisako G" last="Higashi">Hisako G. Higashi</name><name sortKey="Iourtov, Dmitri" sort="Iourtov, Dmitri" uniqKey="Iourtov D" first="Dmitri" last="Iourtov">Dmitri Iourtov</name><name sortKey="Kubrusly, Flavia S" sort="Kubrusly, Flavia S" uniqKey="Kubrusly F" first="Flavia S" last="Kubrusly">Flavia S. Kubrusly</name><name sortKey="Leite, Luciana C C" sort="Leite, Luciana C C" uniqKey="Leite L" first="Luciana C C" last="Leite">Luciana C C. Leite</name><name sortKey="Lucio, Fernanda" sort="Lucio, Fernanda" uniqKey="Lucio F" first="Fernanda" last="Lúcio">Fernanda Lúcio</name><name sortKey="Miyaji, Eliane N" sort="Miyaji, Eliane N" uniqKey="Miyaji E" first="Eliane N" last="Miyaji">Eliane N. Miyaji</name><name sortKey="Miyaki, Cosue" sort="Miyaki, Cosue" uniqKey="Miyaki C" first="Cosue" last="Miyaki">Cosue Miyaki</name><name sortKey="Raw, Isaias" sort="Raw, Isaias" uniqKey="Raw I" first="Isaias" last="Raw">Isaias Raw</name><name sortKey="Sakauchi, Maria Aparecida" sort="Sakauchi, Maria Aparecida" uniqKey="Sakauchi M" first="Maria Aparecida" last="Sakauchi">Maria Aparecida Sakauchi</name><name sortKey="Takata, Celia S" sort="Takata, Celia S" uniqKey="Takata C" first="Celia S" last="Takata">Celia S. Takata</name></noCountry><country name="Brésil"><region name="État de São Paulo"><name sortKey="Quintilio, Wagner" sort="Quintilio, Wagner" uniqKey="Quintilio W" first="Wagner" last="Quintilio">Wagner Quintilio</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000873 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000873 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19393709
|texte= Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19393709" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |